Health
Takeda To Develop Zika Vaccine With $312m
By Modupe Gbadeyanka
Japanese firm, Takeda Pharmaceutical Company Limited, has announced that the Biomedical Advanced Research and Development Authority (BARDA) has selected its Vaccine Business Unit to develop a vaccine to support the Zika response in the US and affected regions around the world.
Initial funding from BARDA, which is a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services, is for $19.8 million to cover the vaccine development through Phase 1, with potential funding of up to $312 million if ASPR/BARDA exercises all options to take the vaccine through Phase 3 trials and filing of the Biologics License Application (BLA) in the US.
On February 1, 2016, the World Health Organization declared the Zika outbreak to be a Public Health Emergency of International Concern. On February 8, 2016 the Centers for Disease Control and Prevention (CDC) elevated its Zika response efforts to its highest response level, Level 1. There is no vaccine or medicine for Zika2, and infection during pregnancy can cause a serious birth defect called microcephaly and other severe fetal brain defects.
Current research suggests that Guillain-Barre syndrome (GBS), which is an uncommon sickness of the nervous system, is strongly associated with Zika; however, only a small proportion of people with recent Zika virus infection get GBS. Many people infected with Zika will have no symptoms or mild symptoms that last several days to a week. The virus has spread in recent years into more than 60 countries and territories including the US.
Dr Rajeev Venkayya, Corporate Officer and President of the Global Vaccine Business Unit at Takeda, said: “The Zika emergency demands swift action by governments, public health agencies, medical and scientific communities, industry and others, and partnerships are essential for success.
“Working with BARDA, Takeda is deploying its world-class expertise and capabilities in vaccine development for emerging infectious diseases, and our outstanding team and manufacturing facilities in Hikari, Japan.
“This Zika vaccine program joins our work in dengue, norovirus, our partnership with the Japanese Government on pandemic influenza, and the recently announced partnership with the Bill & Melinda Gates Foundation to help eradicate polio.
“These efforts to develop a vaccine against the Zika virus reinforce Takeda’s commitment to the health of people everywhere, including the most vulnerable populations that are threatened by Zika.”
Given the Japanese Government’s commitment to preparedness for outbreaks of infectious diseases, recently reinforced by Prime Minister Abe at the G7 Summit in Ise-Shima, Japan, Takeda is in discussions with the Cabinet Secretariat of the Prime Minister Office regarding potential participation of Japanese health agencies in this collaboration. Takeda is working with ASPR/BARDA and the Japanese Government to explore these opportunities further.
Under the agreement, Takeda will develop an inactivated, adjuvanted, whole Zika virus vaccine. The objectives of the first stage of the work include developing and producing the investigational vaccine and completing pre-clinical studies, submission of an Investigational New Drug Application (IND) to the US Food and Drug Administration, and execution of a Phase 1 clinical trial. Manufacturing of the vaccine will occur at Takeda’s facilities in Hikari, Japan.
Takeda’s Commitment to Vaccines
Vaccines prevent more than two million deaths each year and have transformed global public health. For 70 years, Takeda has supplied vaccines to protect the health of people in Japan.
Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, norovirus and polio. Our team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs.
Health
Mums Feel Warmth Initiative Raises Postpartum Depression Awareness
By Modupe Gbadeyanka
A transformative webinar to raise awareness on postpartum depression (PPD) by nursing mothers has been organised by MSc Media and Communication students from the School of Media and Communications of the Pan-Atlantic University.
The programme titled Beyond Baby Blues: Understanding and Overcoming Postpartum Depression was held on January 7, 2025.
It was put together by the students under the Mums Feel Warmth initiative, with experts in the field invited to speak on the matter aimed at empowering mothers and fostering a sense of reassurance.
The webinar was to highlight the journey through postpartum depression, offering a message of hope, resilience, and the importance of mental health support for mothers everywhere.
One of the speakers, Dr Laja Odunuga, who is the Care Coordinator for AVON HMO, explained the difference between the common “baby blues” and the more severe, long-lasting PPD.
The discussion highlighted how PPD can manifest not just as sadness but through severe fatigue, disconnection from the newborn, and loss of interest in activities, which can last well beyond the typical two-week period associated with baby blues.
Another expert, Ms Otomfon Ibanga, the Assistant Lead Nurse for Q-Life Family Clinic, emphasised the role of support systems, urging families and friends to be vigilant for signs of PPD and to provide a nurturing environment.
She also discussed prevention strategies, including prenatal planning for support structures and post-delivery management through therapy or medication.
On his part, Dr Chimaraoke Obialo, who is the Medical Director of Life Amada Health Consultancy, addressed the stigma surrounding PPD, advocating for education to transform societal perceptions from judgement to support.
The webinar underscored the need for community involvement, not just in recognising symptoms but in actively participating in the healing process by offering emotional and practical support.
The Mums Feel Warmth webinar was more than just an educational session; it was a call to action for society to embrace and support new mothers dealing with PPD.
By fostering open conversations and providing platforms for sharing experiences, Mums Feel Warmth continues to lead the charge against the stigma of PPD.
The commitment shown by the panellists and attendees alike promises a future where every mother has access to the understanding and care needed to navigate through the complexities of postpartum depression, ensuring that the joy of motherhood is not overshadowed by mental health challenges.
Mums Feel Warmth, with its core values of empathy, compassion, hope, community, and education, speaks to the Sustainable Development Goal 3, advocating for good health and well-being.
The initiative is breaking the silence around PPD, a condition that can significantly impact new mothers in the critical period following childbirth.
Health
NCDC Monitors HMPV Situation, Affirms Nigeria at Moderate Risk
By Adedapo Adesanya
The Nigeria Centre for Disease Control (NCDC) says the country is at “moderate” risk for Human Metapneumovirus (HMPV), a virus that leads to an upper respiratory tract infection with symptoms like cough, fever, and nasal congestion.
In a public health advisory, the Nigerian health agency said the federal government is closely monitoring the outbreak of the virus and is taking safety measures to “strengthen the country’s preparedness and response capacity”.
Recent reports indicate a significant rise in HMPV cases in China, as well as increased respiratory infections linked to HMPV in countries such as the United Kingdom (UK), France, and Germany, particularly during the winter season.
The NCDC said it conducted a risk assessment for the HMPV in collaboration with the Federal Ministry of Health and partners such as the World Health Organization (WHO), the US Centres for Disease Control and Prevention (USCDC), and the UK Health Security Agency (UKHSA).
“The assessment classified the risk of HMPV for Nigeria as moderate. This evaluation will inform and guide preparedness efforts, decision-making, and response strategies to mitigate potential impacts,” the advisory said.
It said the NCDC is working to give Nigerians “timely, accurate information and guidance to keep the Nigerian public informed and prepared”.
NCDC noted that it “in collaboration with Port Health Authorities, is taking proactive steps to ensure robust preparedness at all international points of entry (PoEs) in response to the dynamic risk assessment for Human Metapneumovirus (HMPV).
“These measures are designed to mitigate the potential risk of HMPV transmission through international travel.”
HMPV was first identified in the Netherlands in 2001 and the virus spreads through direct contact between people or when someone touches surfaces contaminated with it.
Children under two are most vulnerable to the virus alongside those with weakened immune systems such as the elderly and those with advanced cancer, according to medical experts.
There have also been worries that this could be like COVID-19, but experts have eased the fear as they are not similar because pandemics are typically caused by novel pathogens, which is not the case for HMPV.
Health
Digitising Healthcare With Local Realities in Mind: Shaping The Future of Healthcare in Africa
eHealth Africa (eHA) has urged governments and stakeholders to explore the critical factors beyond technology that are essential for the deployment of digital health solutions for the long-term success of public health systems across Africa. Data-backed interventions will help streamline operations and enable the formulation of interventions that appreciate the cultural norms when addressing the immediate needs of different communities within the region.
Speaking during a panel session at the Global Digital Health Forum 2024 in Nairobi, eHealth Africa’s Executive Director Atef Fawaz emphasised the importance of integrating technology with local cultures and addressing community-specific needs. “Understanding the unique healthcare challenges in each country allows us to deploy tech solutions that truly make an impact.”For instance, eHealth Africa successfully delivered over 5.8 million vaccines (5,801,209) to 351 primary healthcare facilities across states in Nigeria which was made possible through the deployment of the innovative Logistics Management Information System (LoMIS) application.
“The system significantly improved the availability of vaccines for Routine Immunisation (RI), ensuring timely and efficient distribution while eliminating stockouts at primary healthcare facilities. This intervention highlights our commitment to strengthening immunisation programs and enhancing healthcare delivery at the grassroots level,” he said.
In his contribution, Abdulhamid Yahaya, the Deputy Director of Global Health Informatics highlighted the need to understand the local cultural, social, and regulatory landscape to build solutions that are designed with local realities in mind.
eHealth Africa Board Member Micheline Ntiru said using technology provided stakeholders among them global health leaders, tech innovators, and development experts as well as local communities a platform to create the right solutions that work within the constraints of each community, and with the support of local leadership.
For instance, local health workers have been using mobile-based reminder systems to improve compliance and overall health outcomes while some local immunisation centres have been sending SMS reminders to parents as well as to provide educational messages about the diseases they protect against. Mobile phones, now available in nearly 80 per cent of African homes, can also be used during emergencies to dispatch mass announcements about satellite clinic locations and schedules.
According to the World Health Organisation, increased use of the Internet, email, social networking sites and availability of mobile phones facilitates the deployment of eHealth solutions, applications and services towards the improvement of national health systems. The use of technological eHealth solutions could also be used to encourage positive lifestyle changes to prevent and control common diseases.
The panel moderated by Ota Akhigbe, Director of Partnerships and Programs comprised of Ms Ntiru (Delta40 ventures), Mr Yahaya (eHealth Africa), Chief Impact Officer at Tiko – Serah Malaba, Dr Olamide Okulaja (Maisha Meds), Audere Chief Executive Officer Dr Dino Rech, and Rachel Alladian from Jacaranda. They discussed how strategic partnerships, regulatory compliance, and a deep understanding of local contexts are crucial for driving digital health innovations that can succeed in diverse regions.
The GDHF forum was attended by health scholars, researchers, and representatives from the Ministry of Health in Ethiopia, Tanzania, Kenya, Malaysia, Somalia and Sri Lanka as well as representatives from the World Bank, medicine manufacturers, technology vendors, UN agencies among others.
-
Feature/OPED5 years ago
Davos was Different this year
-
Travel/Tourism8 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz2 years ago
Estranged Lover Releases Videos of Empress Njamah Bathing
-
Banking7 years ago
Sort Codes of GTBank Branches in Nigeria
-
Economy2 years ago
Subsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking2 years ago
First Bank Announces Planned Downtime
-
Sports2 years ago
Highest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn
-
Technology4 years ago
How To Link Your MTN, Airtel, Glo, 9mobile Lines to NIN